公开(公告)号：US20240131136A1

公开(公告)日：2024-04-25

申请号：US18386593

申请日：2023-11-01

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Elisabeth Marie Monique BERTAUD ,  Ralph Leon BIEMANS ,  Nicolas Jean Benoit MONIOTTE ,  Laurent Bernard Jean STRODIOT

IPC: A61K39/09 ,  A61K47/64

CPC classification number: A61K39/092 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/6087

Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.

公开(公告)号：US20240226261A9

公开(公告)日：2024-07-11

申请号：US18386593

申请日：2023-11-02

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Elisabeth Marie Monique BERTAUD ,  Ralph Leon BIEMANS ,  Nicolas Jean Benoit MONIOTTE ,  Laurent Bernard Jean STRODIOT

IPC: A61K39/09 ,  A61K47/64

CPC classification number: A61K39/092 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/6087

Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.

公开(公告)号：US20180303923A1

公开(公告)日：2018-10-25

申请号：US15769542

申请日：2016-10-19

Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA

Inventor： Elisabeth Marie Monique BERTAUD ,  Ralph Leon BIEMANS ,  Nicolas Jean Benoit MONIOTTE ,  Laurent Bernard Jean STRODIOT

IPC: A61K39/09 ,  A61K47/64

CPC classification number: A61K39/092 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/6087 ,  A61K2039/62 ,  A61K2039/70

Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.